{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:36:23Z","timestamp":1793957783320,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100016323","name":"Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetric & Gynecology and Pediatrics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.xphs.2025.104051","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T15:48:22Z","timestamp":1762012102000},"page":"104051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetic prediction and dosage adjustment of enoxaparin administration in pregnant women with renal insufficiency: A FAERS-PBPK modeling study"],"prefix":"10.1016","volume":"115","author":[{"given":"Guimu","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintuo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiguang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5629-0348","authenticated-orcid":false,"given":"Jinhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2025.104051_bib0001","doi-asserted-by":"crossref","DOI":"10.1080\/14767058.2024.2448504","article-title":"Trend, clinical characteristics, and pregnancy outcomes of pregnancy associated venous thromboembolism: a retrospective analysis of nearly 10 years","volume":"38","author":"Wang","year":"2025","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"1","key":"10.1016\/j.xphs.2025.104051_bib0002","doi-asserted-by":"crossref","first-page":"62","DOI":"10.23736\/S0026-4806.24.09242-5","article-title":"Venous thromboembolism during pregnancy and postpartum period: an updated review","volume":"116","author":"Mojaddedi","year":"2025","journal-title":"Minerva Med"},{"issue":"2","key":"10.1016\/j.xphs.2025.104051_bib0003","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0306-3356(21)00083-2","article-title":"Venous thromboembolism and pregnancy","volume":"8","author":"Bonnar","year":"1981","journal-title":"Clin Obstet Gynaecol"},{"issue":"4","key":"10.1016\/j.xphs.2025.104051_bib0004","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.4081\/hr.2015.5844","article-title":"The anti-factor Xa range for low molecular weight heparin thromboprophylaxis","volume":"7","author":"Wei","year":"2015","journal-title":"Hematol Rep"},{"issue":"1","key":"10.1016\/j.xphs.2025.104051_bib0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11239-015-1314-3","article-title":"Pharmacology of anticoagulants used in the treatment of venous thromboembolism","volume":"41","author":"Nutescu","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"22","key":"10.1016\/j.xphs.2025.104051_bib0006","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1182\/bloodadvances.2018024802","article-title":"American society of hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy","volume":"2","author":"Bates","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.xphs.2025.104051_bib0007","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/clpt.2008.73","article-title":"Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy","volume":"84","author":"Lebaudy","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2025.104051_bib0008","unstructured":"FDA Approved Drug Products: lovenox (enoxaparin sodium injection), for subcutaneous and intravenous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020164s116lbl.pdf."},{"issue":"9","key":"10.1016\/j.xphs.2025.104051_bib0009","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/0003-4819-144-9-200605020-00011","article-title":"Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency","volume":"144","author":"Lim","year":"2006","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.xphs.2025.104051_bib0010","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1177\/0091270003253420","article-title":"Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin","volume":"43","author":"Chow","year":"2003","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2025.104051_bib0011","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1067\/mcp.2002.127114","article-title":"The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers","volume":"72","author":"Sanderink","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"2 Suppl)","key":"10.1016\/j.xphs.2025.104051_bib0012","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.xphs.2025.104051_bib0013","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1055\/s-0042-1753546","article-title":"Perinatal outcomes in women with chronic kidney diseases","volume":"44","author":"Zilli","year":"2022","journal-title":"Rev Bras Ginecol Obstet"},{"issue":"1","key":"10.1016\/j.xphs.2025.104051_bib0014","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12882-019-1560-2","article-title":"Clinical practice guideline on pregnancy and renal disease","volume":"20","author":"Wiles","year":"2019","journal-title":"BMC Nephrol"},{"issue":"11","key":"10.1016\/j.xphs.2025.104051_bib0015","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2215\/CJN.09250914","article-title":"A systematic review and meta-analysis of outcomes of pregnancy in CKD and CKD outcomes in pregnancy","volume":"10","author":"Zhang","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9606","key":"10.1016\/j.xphs.2025.104051_bib0016","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0140-6736(08)60074-4","article-title":"Epidemiology and causes of preterm birth","volume":"371","author":"Goldenberg","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.xphs.2025.104051_bib0017","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1160\/TH06-09-0513","article-title":"Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study","volume":"97","author":"Mahe","year":"2007","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.xphs.2025.104051_bib0018","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000040922","article-title":"Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin","volume":"101","author":"Brennand","year":"1999","journal-title":"Acta Haematol"},{"issue":"5 Pt 1","key":"10.1016\/j.xphs.2025.104051_bib0019","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0002-9378(99)70091-8","article-title":"Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy","volume":"181","author":"Casele","year":"1999","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.xphs.2025.104051_bib0020","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2337\/dc23-1344","article-title":"Metformin-cimetidine drug interaction and risk of lactic acidosis in renal failure: a pharmacovigilance-pharmacokinetic appraisal","volume":"47","author":"Xie","year":"2024","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.xphs.2025.104051_bib0021","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s40262-017-0594-5","article-title":"A physiologically based pharmacokinetic model for pregnant women to predict the pharmacokinetics of drugs metabolized via several enzymatic pathways","volume":"57","author":"Dallmann","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.xphs.2025.104051_bib0022","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/ijgo.13150","article-title":"Physiologically based pharmacokinetic modeling (PBPK's) prediction potential in clinical pharmacology decision making during pregnancy","volume":"150","author":"Eke","year":"2020","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"10.1016\/j.xphs.2025.104051_bib0023","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/psp4.70007","article-title":"Toward precision dosing of lamotrigine during pregnancy: physiologically based pharmacokinetic modeling and simulation","volume":"14","author":"Qian","year":"2025","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.xphs.2025.104051_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106707","article-title":"Physiologically based pharmacokinetic modeling to predict maternal pharmacokinetics and fetal carbamazepine exposure during pregnancy","volume":"194","author":"Chen","year":"2024","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.104051_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106349","article-title":"Application of PBPK modeling in predicting maternal and fetal pharmacokinetics of levetiracetam during pregnancy","volume":"181","author":"Chen","year":"2023","journal-title":"Eur J Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2025.104051_bib0026","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/psp4.12300","article-title":"Applied concepts in PBPK modeling: how to extend an open systems pharmacology model to the special population of pregnant women","volume":"7","author":"Dallmann","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2025.104051_bib0027","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.thromres.2014.07.025","article-title":"Characterization of antithrombin levels in pregnancy","volume":"134","author":"James","year":"2014","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.xphs.2025.104051_bib0028","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/clpt.2011.320","article-title":"The role of physiologically based pharmacokinetic modeling in regulatory review","volume":"91","author":"Huang","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"6 Suppl","key":"10.1016\/j.xphs.2025.104051_bib0029","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th Edition)","volume":"133","author":"Geerts","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.xphs.2025.104051_bib0030","unstructured":"Venous thromboembolism (VTE) prophylaxis in pregnancy and the puerperium. https:\/\/www.health.qld.gov.au\/__data\/assets\/pdf_file\/0011\/140024\/g-vte.pdf."},{"key":"10.1016\/j.xphs.2025.104051_bib0031","doi-asserted-by":"crossref","first-page":"A149.3","DOI":"10.1136\/archdischild-2014-306576.439","article-title":"PMM.86\u2005Use of enoxaparin and anti-factor Xa monitoring in a renal obstetric cohort","volume":"99","author":"Sarween","year":"2014","journal-title":"Arch Dis Child-FETAL"},{"issue":"5","key":"10.1016\/j.xphs.2025.104051_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027180","article-title":"Adverse pregnancy outcomes and long-term risk of maternal renal disease: a systematic review and meta-analysis protocol","volume":"9","author":"Barrett","year":"2019","journal-title":"BMJ Open"},{"issue":"24","key":"10.1016\/j.xphs.2025.104051_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13247757","article-title":"Role of antiplatelets and anticoagulation therapies in pregnancy","volume":"13","author":"Zachariah","year":"2024","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.xphs.2025.104051_bib0034","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1016\/j.ekir.2022.09.029","article-title":"Summary of the Dutch practice guideline on pregnancy wish and pregnancy in CKD","volume":"7","author":"de Jong","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"Suppl 1","key":"10.1016\/j.xphs.2025.104051_bib0035","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.thromres.2008.08.005","article-title":"Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency","volume":"123","author":"Clark","year":"2008","journal-title":"Thromb Res"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925005052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925005052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:47:55Z","timestamp":1773305275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925005052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0022354925005052"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104051","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic prediction and dosage adjustment of enoxaparin administration in pregnant women with renal insufficiency: A FAERS-PBPK modeling study","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104051"}}